AbbVie will test lutikizumab together with ABBV-295, the amylin-based obesity drug it licensed from Danish biotech Gubra, ...

China has more house dust mite allergy sufferers than any other country, but fewer than 1 million of an estimated 100 million ...

All major hearing aid makers are launching new premium devices at the same time, but Søren Nielsen expects audiologists to ...

On Thursday evening, Bioporto was able to delight investors with a US marketing approval for the kidney test NGAL for patients between the ages of three months and 21 years. The US Food and Drug ...

EU panel backs Eli Lilly’s Foundayo obesity pill Eli Lilly is still awaiting final approval from the European Commission.

In May, Demant achieved its highest ever market share in the Veterans Affairs (VA) sales channel. This follows the launch of the top product Oticon Intent, which was made available on May 1. And it ...

Lundbeck's product development lead has passed away Lars Bang spent his entire professional career at Lundbeck and was a member of the company’s senior management team.

”Novo aims to be ’the world’s most AI-driven healthcare company,’” says CEO Mike Doustdar.

Former GN executive to lead Nordic expansion of AI cell-therapy company that took over Novo program Peter Aksel Villadsen leaves GN after six years to build up Cellular Intelligence in the Nordics, as ...